Head of Investor Relations
Candel Therapeutics, Inc. (CADL)Equibles does not estimate personal net worth.
Get an email with a short summary when Candel Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CADL alertsTed Jenkins is recorded as Head of Investor Relations at Candel Therapeutics, Inc. (CADL). Ted Jenkins has spoken on 1 investor event across 1 company, most recently for Candel Therapeutics, Inc. on May 15, 2026. Candel Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Candel Therapeutics, Inc. includes Paul Peter Tak (CEO and Board Member), Charles Schoch (CFO), Jason Amello (CFO) and 7 others.
“Earlier today, the company presented extended follow-up data from the Phase III clinical trial in patients with intermediate to high-risk localized prostate cancer during an oral plenary presentation of the 2026 American Urological Association Annual Meeting in Washington, D.C. We are pleased to conduct a public…”
Biotechnology · Healthcare
Head of Investor Relations
